Form 4: Brainstorm Cell Therapeutics Director Acquires Shares Through Restricted Stock Units

Director Jacob A. Frenkel acquired 40,000 shares of Brainstorm Cell Therapeutics through restricted stock units, vesting in two tranches.

Summary

• Jacob A. Frenkel, a director of Brainstorm Cell Therapeutics Inc., acquired 40,000 shares of common stock on January 1, 2025.
• The acquisition was through restricted stock units (RSUs) awarded under the 2014 Global Share Option Plan.
• 50% of the RSUs vested on the grant date, and the remaining 50% will vest six months later, contingent upon continued employment.
• The price per share was $0.00.
• Following the transaction, Frenkel beneficially owns 43,777 shares.
• The filing also reflects a 1-for-15 reverse stock split that took effect on October 1, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares can be seen as a positive sign, but it's a routine transaction related to previously granted compensation.

Positives

• Director's acquisition of shares may signal confidence in the company's future prospects.

Future Outlook

The remaining 50% of the awarded RSUs will vest six months from the grant date, contingent on continued employment.

Industry Context

Form 4 filings are routine disclosures for company insiders and provide transparency into their transactions in the company's stock. This filing indicates a director's acquisition of shares, which can be interpreted as a positive signal.

Stakeholder Impact

• The director's stock acquisition could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Brainstorm Cell Therapeutics, Director, Jacob A. Frenkel, RSUs, Stock Acquisition, Beneficial Ownership, Reverse Stock Split